Global Cancer Monoclonal Antibodies Market Report 2024

Cancer Monoclonal Antibodies Global Market Report 2023 – By Monoclonal Antibody Therapies (Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), Other Monoclonal Antibody Therapies), By Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, Other Applications), By End User (Hospitals And Clinics, Research Laboratories, Pharmacies, Other End Users) – Market Size, Trends, And Global Forecast 2023-2032

Starting Price : $5000.00 | Pages : 250 | Published : January 2023 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Cancer Monoclonal Antibodies Market

Proud Members Of

checkslacipN checkaoirsN checkscipN

Cancer monoclonal antibodies refer to a particular class of protein created in a lab that has the ability to bind to certain bodily targets, such as antigens on the surface of cancer cells. Each monoclonal antibody is designed to bind to a single antigen, and there are many different types of monoclonal antibodies.

The main types of monoclonal antibody therapies in cancer are bevacizumab (Avastin), rituximab (Rituxan), trastuzumab (Herceptin), cetuximab (Erbitux), and panitumumab (Vectibix). Avastin is a medication that helps people with wet age-related macular degeneration (AMD). It can also be employed to treat diabetic eye problems and other retinal issues. It's administered into the eye to help delay the loss of eyesight caused by certain disorders. The different applications include breast cancer, blood cancer, liver cancer, brain cancer, colorectal cancer, and others, and involve various sectors such as hospitals and clinics, research laboratories, pharmacies, and others.

The global cancer monoclonal antibodies market is segmented -

1) By Monoclonal Antibody Therapies: Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), Other Monoclonal Antibody Therapies

2) By Application: Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, Other Applications

3) By End User: Hospitals And Clinics, Research Laboratories, Pharmacies, Other End Users

The global cancer monoclonal antibodies market size grew from $56 billion in 2022 to $62.46 billion in 2023 at a compound annual growth rate (CAGR) of 11.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of cancer monoclonal antibodies is expected to grow from $98.11 billion in 2027 at a CAGR of 12.0%.

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the cancer monoclonal antibody market. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for growth of the cancer monoclonal antibody market.

Major players in the cancer monoclonal antibody market are Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genmab AS, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Merck & Co., and Spectrum Pharmaceuticals.

The high costs involved in the development of monoclonal antibodies with advanced techniques act as a major restraint on the market due to the complex production process, expensive biological and chemical materials, and clinical trials, as well as the required safety, efficacy, and quality tests. Advanced equipment is required for the large-scale production of monoclonal antibodies that encompass multiple disulfide bonds and post-translational modifications, and this equipment is expensive. Clinical efficacy is usually achieved by injecting large amounts of monoclonal antibodies into the system, which means that large quantities are required to be produced for each treatment, thus increasing the cost. According to the American Journal of Managed Care, the annual price of monoclonal antibody therapies used in oncology and haematology is about $100,000 higher than that of those used in other disease states. Thus, the high development costs of using these advanced techniques will restrain cancer monoclonal antibodies market growth.

Companies in the cancer monoclonal antibody market are increasing their product innovation through strategic collaborations. To sustain themselves in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with academic and research institutions in this market by way of partnerships and in- or out-licensing deals, this trend has been increasing over the past few years. For instance, in September 2020, AbbVie and I-Mab entered into a strategic partnership for the development and commercialization of lemzoparlimab (also known as TJC4), which is a monoclonal antibody drug used to treat multiple cancers.

In March 2020, Gilead Sciences, a US-based biopharmaceutical company, announced its decision to acquire Forty Seven for $4.9 billion. This acquisition is expected to strengthen Gilead’s immuno-oncology R&D portfolio with the addition of Forty Seven’s investigational lead product candidate, magrolimab. Magrolimab is a monoclonal antibody in clinical development for the treatment of several cancers. Forty Seven Inc. is a clinical-stage immuno-oncology company that develops therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licenced from Stanford University.

North America was the largest region in the cancer monoclonal antibodies market in 2022.

The regions covered in the global cancer monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the cancer monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA.

The cancer monoclonal antibody market consists of sales of pembrolizumab, blinatumomab, casirivimab, and imdevimab. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products.

The cancer monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides cancer monoclonal antibodies market statistics, such as cancer monoclonal antibodies industry global market size, regional shares, competitors with a cancer monoclonal antibodies market share, detailed cancer monoclonal antibodies market segments, market trends and opportunities, and any other information you may require to thrive in the ca This cancer monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

    Table Of Contents

    1. Cancer Monoclonal Antibodies Market Executive Summary

    2. Table of Contents

    3. List of Figures

    4. List of Tables

    5. Report Structure

    6. Introduction

    6.1. Segmentation By Geography

    6.2. Segmentation By Monoclonal Antibody Therapies

    6.3. Segmentation By Application

    6.4. Segmentation By End User

    7. Cancer Monoclonal Antibodies Market Characteristics

    7.1. Market Definition

    7.2. Market Segmentation By Monoclonal Antibody Therapies

    7.2.1. Avastin

    7.2.2. Herceptin

    7.2.3. Keytruda

    7.2.4. Opdivo

    7.2.5. Darzalex

    7.2.6. Perjeta

    7.2.7. Others

    7.3. Market Segmentation By Application

    7.3.1. Breast Cancer

    7.3.2. Blood Cancer

    7.3.3. Lung Cancer

    7.3.4. Brain Tumor

    7.3.5. Colorectal Cancer

    7.3.6. Brain Tumor

    7.3.7. Cervical cancer

    7.3.8. Gastric cancer

    7.3.9. Others

    7.4. Market Segmentation By End User

    7.4.1. Hospitals

    7.4.2. Research Laboratories

    7.4.3. Others

    8. Cancer Monoclonal Antibodies Market Trends And Strategies

    8.1. Product Innovation Through Strategic Collaborations

    8.2. Humanized Cancer Monoclonal Antibodies

    8.3. Investment in Artificial Intelligence

    8.4. Technological Advancements in Gene Sequencing and Target Gene Selection

    8.5. R&D Investments

    8.6. Investment in Targeted and Combination Therapy

    9. Impact Of COVID-19 On The Cancer Monoclonal Antibodies Market

    9.1. Introduction

    9.2. Supply Chain Issues

    9.3. Clinical Trial Delays

    9.4. Impact On Major Players

    9.5. Future Outlook

    10. Global Cancer Monoclonal Antibodies Market Size And Growth

    10.1. Market Size

    10.2. Historic Market Growth, 2015 – 2020, Value ($ Million)

    10.2.1. Drivers Of The Market 2015 – 2020

    10.2.2. Restraints of The Market 2015 – 2020

    10.3. Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    10.3.1. Drivers Of The Market 2020 – 2025

    10.3.2. Restraints On The Market 2020 – 2025

    11. Global Cancer Monoclonal Antibodies Market Segmentation

    11.1. Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    11.2. Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    11.3. Global Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    12. Cancer Monoclonal Antibodies Market, Regional And Country Analysis

    12.1. Global Cancer Monoclonal Antibodies Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    12.2. Global Cancer Monoclonal Antibodies Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    13. Asia-Pacific Cancer Monoclonal Antibodies Market

    13.1. Asia-Pacific Cancer Monoclonal Antibodies Market Overview

    13.1.1. Region Information

    13.1.2. Market Information

    13.1.3. Background Information

    13.1.4. Government Initiatives

    13.1.5. Regulatory Bodies

    13.1.6. Regulations

    13.1.7. Major Associations

    13.1.8. Taxes Levied

    13.1.9. Corporate Tax Structure

    13.1.10. Investments

    13.1.11. Major Companies

    13.2. Asia-Pacific Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    13.3. Asia-Pacific Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    13.4. Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    13.5. Asia-Pacific Cancer Monoclonal Antibodies Market: Country Analysis

    13.6. China Cancer Monoclonal Antibodies Market

    13.7. China Cancer Monoclonal Antibodies Market Overview

    13.7.1. Region Information

    13.7.2. Market Information

    13.7.3. Background Information

    13.7.4. Government Initiatives

    13.7.5. Regulatory Bodies

    13.7.6. Regulations

    13.7.7. Major Associations

    13.7.8. Taxes Levied

    13.7.9. Corporate Tax Structure

    13.7.10. Investments

    13.7.11. Major Companies

    13.8. China Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    13.9. China Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    13.10. China Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    13.11. India Cancer Monoclonal Antibodies Market

    13.12. India Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    13.13. India Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    13.14. India Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    13.15. Japan Cancer Monoclonal Antibodies Market

    13.16. Japan Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    13.17. Japan Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    13.18. Japan Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    13.19. Australia Cancer Monoclonal Antibodies Market

    13.20. Australia Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    13.21. Australia Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    13.22. Australia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    13.23. Indonesia Cancer Monoclonal Antibodies Market

    13.24. Indonesia Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    13.25. Indonesia Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    13.26. Indonesia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    13.27. South Korea Cancer Monoclonal Antibodies Market

    13.28. South Korea Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    13.29. South Korea Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    13.30. South Korea Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    14. Western Europe Cancer Monoclonal Antibodies Market

    14.1. Western Europe Cancer Monoclonal Antibodies Market Overview

    14.1.1. Region Information

    14.1.2. Market Information

    14.1.3. Background Information

    14.1.4. Government Initiatives

    14.1.5. Regulations

    14.1.6. Regulatory Bodies

    14.1.7. Major Associations

    14.1.8. Taxes Levied

    14.1.9. Corporate Tax Structure

    14.1.10. Investments

    14.1.11. Major Companies

    14.2. Western Europe Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    14.3. Western Europe Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    14.4. Western Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    14.5. Western Europe Cancer Monoclonal Antibodies Market: Country Analysis

    14.6. UK Cancer Monoclonal Antibodies Market

    14.7. UK Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    14.8. UK Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    14.9. UK Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    14.10. Germany Cancer Monoclonal Antibodies Market

    14.11. Germany Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    14.12. Germany Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    14.13. Germany Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    14.14. France Cancer Monoclonal Antibodies Market

    14.15. France Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    14.16. France Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    14.17. France Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    15. Eastern Europe Cancer Monoclonal Antibodies Market

    15.1. Eastern Europe Cancer Monoclonal Antibodies Market Overview

    15.1.1. Region Information

    15.1.2. Market Information

    15.1.3. Background Information

    15.1.4. Government Initiatives

    15.1.5. Regulatory Bodies

    15.1.6. Regulations

    15.1.7. Major Associations

    15.1.8. Taxes Levied

    15.1.9. Corporate Tax Structure

    15.1.10. Investments

    15.1.11. Major Companies

    15.2. Eastern Europe Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    15.3. Eastern Europe Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    15.4. Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    15.5. Eastern Europe Cancer Monoclonal Antibodies Market: Country Analysis

    15.6. Russia Cancer Monoclonal Antibodies Market

    15.7. Russia Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    15.8. Russia Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    15.9. Russia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    16. North America Cancer Monoclonal Antibodies Market

    16.1. North America Cancer Monoclonal Antibodies Market Overview

    16.1.1. Region Information

    16.1.2. Market Information

    16.1.3. Background Information

    16.1.4. Government Initiatives

    16.1.5. Regulations

    16.1.6. Regulatory Bodies

    16.1.7. Major Associations

    16.1.8. Taxes And Duties

    16.1.9. Corporate Tax Structure

    16.1.10. Investments

    16.1.11. Major Companies

    16.2. North America Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    16.3. North America Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    16.4. North America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    16.5. North America Cancer Monoclonal Antibodies Market: Country Analysis

    16.6. USA Cancer Monoclonal Antibodies Market

    16.7. USA Cancer Monoclonal Antibodies Market Overview

    16.7.1. Region Information

    16.7.2. Market Information

    16.7.3. Background Information

    16.7.4. Government Initiatives

    16.7.5. Regulatory Bodies

    16.7.6. Regulations

    16.7.7. Major Associations

    16.7.8. Taxes Levied

    16.7.9. Corporate Tax Structure

    16.7.10. Investments

    16.7.11. Major Companies

    16.8. USA Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    16.9. USA Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    16.10. USA Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    17. South America Cancer Monoclonal Antibodies Market

    17.1. South America Cancer Monoclonal Antibodies Market Overview

    17.1.1. Region Information

    17.1.2. Market Information

    17.1.3. Background Information

    17.1.4. Government Initiatives

    17.1.5. Regulations

    17.1.6. Regulatory Bodies

    17.1.7. Major Associations

    17.1.8. Taxes And Duties

    17.1.9. Corporate Tax Structure

    17.1.10. Investments

    17.1.11. Major Companies

    17.2. South America Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    17.3. South America Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    17.4. South America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    17.5. South America Cancer Monoclonal Antibodies Market: Country Analysis

    17.6. Brazil Cancer Monoclonal Antibodies Market

    17.7. Brazil Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    17.8. Brazil Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    17.9. Brazil Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    18. Middle East Cancer Monoclonal Antibodies Market

    18.1. Middle East Cancer Monoclonal Antibodies Market Overview

    18.1.1. Region Information

    18.1.2. Market Information

    18.1.3. Background Information

    18.1.4. Government Initiatives

    18.1.5. Regulations

    18.1.6. Regulatory Bodies

    18.1.7. Major Associations

    18.1.8. Taxes Levied

    18.1.9. Corporate Tax Structure

    18.1.10. Investments

    18.1.11. Major Companies

    18.2. Middle East Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    18.3. Middle East Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    18.4. Middle East Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    19. Africa Cancer Monoclonal Antibodies Market

    19.1. Africa Cancer Monoclonal Antibodies Market Overview

    19.1.1. Region Information

    19.1.2. Market Information

    19.1.3. Background Information

    19.1.4. Government Initiatives

    19.1.5. Regulations

    19.1.6. Regulatory Bodies

    19.1.7. Major Associations

    19.1.8. Taxes And Duties

    19.1.9. Corporate Tax Structure

    19.1.10. Investments

    19.1.11. Major Companies

    19.2. Africa Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

    19.3. Africa Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

    19.4. Africa Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

    20. Global Cancer Monoclonal Antibodies Market Competitive Landscape

    20.1. Company Profiles

    20.2. F. Hoffmann-La Roche Ltd

    20.2.1. Company Overview

    20.2.2. Products And Services

    20.2.3. Business Strategy

    20.2.4. Financial Overview

    20.3. Merck & Co., Inc.

    20.3.1. Company Overview

    20.3.2. Products And Services

    20.3.3. Business Strategy

    20.3.4. Financial Overview

    20.4. Bristol Myers Squibb Company

    20.4.1. Company Overview

    20.4.2. Products And Services

    20.4.3. Business Strategy

    20.4.4. Financial Overview

    20.5. Johnson & Johnson

    20.5.1. Company Overview

    20.5.2. Products And Services

    20.5.3. Business Strategy

    20.5.4. Financial Overview

    20.6. Amgen Inc.

    20.6.1. Company Overview

    20.6.2. Products And Services

    20.6.3. Business Strategy

    20.6.4. Financial Overview

    21. Key Mergers And Acquisitions In The Cancer Monoclonal Antibodies Market

    21.1. Ecolab Inc. To Acquire Purolite

    21.2. Exelixis Inc. Acquired Gamamabs Pharma SA’s AMHR2 Antibody Technology

    21.3. Sanofi Acquired Kymab Group Ltd.

    21.4. Boehringer Ingelheim Acquired Preclinical Antibody Pipeline From Northern Biologics Inc.

    21.5. Servier Acquired Symphogen A/S

    21.6. Gilead Sciences Acquired Forty Seven

    21.7. True North Acquired Stake In Biocon Biologics

    21.8. Catalent Inc. Acquired Bristol Myers Squibb’s Oral Dose Manufacturing Facility

    21.9. Bristol Myers Acquired Celgene

    22. Cancer Monoclonal Antibodies Market Opportunities And Strategies

    22.1. Global Cancer Monoclonal Antibodies Market In 2025 – Countries Offering Most New Opportunities

    22.2. Global Cancer Monoclonal Antibodies Market In 2025 – Segments Offering Most New Opportunities

    22.3. Global Cancer Monoclonal Antibodies Market In 2025 – Growth Strategies

    22.3.1. Market Trend Based Strategies

    22.3.2. Competitor Strategies

    23. Cancer Monoclonal Antibodies Market, Conclusions and Recommendations

    23.1. Conclusions

    23.2. Recommendations

    23.2.1. Product

    23.2.2. Place

    23.2.3. Price

    23.2.4. Promotion

    23.2.5. People

    24. Appendix

    24.1. Market Data Sources

    24.2. Research Methodology

    24.3. Currencies

    24.4. Research Inquiries

    24.5. The Business Research Company

    24.6. Copyright and Disclaimer

List Of Tables

    Table 1: Global Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Table 2: Global Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 3: Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 4: Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 5: Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 6: Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 7: Global Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 8: Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 9: Global Cancer Monoclonal Antibodies Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 10: Global Cancer Monoclonal Antibodies Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 11: Global Cancer Monoclonal Antibodies Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 12: Global Cancer Monoclonal Antibodies Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 13: Asia Pacific GDP Per Capita, 2015-2020, $
  • Table 14: Asia Pacific, Population By Age Group, By Country, 2015-2023, Thousands
  • Table 15: Asia Pacific Cancer Prevalence, Estimated Average Expenditure, 2019, $
  • Table 16:  Asia-Pacific Oncology Drugs Market, 2015-2025, $Billion
  • Table 17: Asia-Pacific Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Table 18: Asia-Pacific Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 19: Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 20: Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 21: China GDP Per Capita, 2015-2020, $
  • Table 22: China, Population By Age Group, 2015-2023, Thousands
  • Table 23: China Cancer Prevalence, Estimated Average Expenditure, 2019, $
  • Table 24:  China Oncology Drugs Market, 2015-2025, $Billion
  • Table 25: China Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Table 26: China Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 27: China Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 28: China Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 29: India Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Table 30: India Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 31: India Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 32: India Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 33: Japan Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Table 34: Japan Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 35: Japan Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 36: Japan Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 37: Australia Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Table 38: Australia Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 39: Australia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 40: Australia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 41: Indonesia Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Table 42: Indonesia Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 43: Indonesia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 44: Indonesia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 45: South Korea Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Table 46: South Korea Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 47: South Korea Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 48: South Korea Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 49: Western Europe GDP Per Capita, 2015-2020, $
  • Table 50: Western Europe Population By Age Group, By Country, 2015-2023, Thousands
  • Table 51: Western Europe Estimated Average Expenditure, Cancer Prevalence, 2019
  • Table 52:  Western Europe Oncology Drugs Market, 2015-2025, $Billion
  • Table 53: Western Europe Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Table 54: Western Europe Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 55: Western Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 56: Western Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 57: UK Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Table 58: UK Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 59: UK Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 60: UK Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 61: Germany Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Table 62: Germany Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 63: Germany Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 64: Germany Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 65: France Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Table 66: France Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 67: France Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 68: France Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 69: Eastern Europe GDP Per Capita, 2015-2020, $
  • Table 70: Eastern Europe Population By Age Group, By Country, 2015-2023, Thousands
  • Table 71: Eastern Europe Estimated Average Expenditure, Cancer Prevalence, 2019
  • Table 72:  Eastern Europe Oncology Drugs Market, 2015-2025, $Billion
  • Table 73: Eastern Europe Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Table 74: Eastern Europe Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 75: Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 76: Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 77: Russia Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Table 78: Russia Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 79: Russia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 80: Russia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 81: North America GDP Per Capita, 2015-2020, $
  • Table 82: North America Population By Age Group, By Country, 2015-2023, Thousands
  • Table 83: North America Estimated Average Expenditure, Cancer Prevalence, 2019
  • Table 84:  North America Oncology Drugs Market, 2015-2025, $Billion
  • Table 85: North America Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Table 86: North America Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 87: North America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 88: North America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 89: USA GDP Per Capita, 2015-2020, $
  • Table 90: USA Population By Age Group, 2015-2023, Thousands
  • Table 91: USA Estimated Average Expenditure, Cancer Prevalence, 2019
  • Table 92:  North America Oncology Drugs Market, 2015-2025, $Billion
  • Table 93: USA Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Table 94: USA Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 95: USA Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 96: USA Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 97: South America GDP Per Capita, 2015-2020, $
  • Table 98: South America Population By Age Group, By Country, 2015-2023, Thousands
  • Table 99: South America Estimated Average Expenditure, Cancer Prevalence, 2019
  • Table 100:  South America Oncology Drugs Market, 2015-2025, $Billion
  • Table 101: South America Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Table 102: South America Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 103: South America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 104: South America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 105: Brazil Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Table 106: Brazil Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 107: Brazil Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 108: Brazil Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 109: Middle East GDP Per Capita, 2015-2020, $
  • Table 110: Middle East Population By Age Group, By Country, 2015-2023, Thousands
  • Table 111:  Middle East Oncology Drugs Market, 2015-2025, $Billion
  • Table 112: Middle East Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Table 113: Middle East Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 114: Middle East Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 115: Middle East Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 116: Africa GDP Per Capita, 2015-2020, $
  • Table 117: Africa Population By Age Group, By Country, 2015-2023, Thousands
  • Table 118:  Africa Oncology Drugs Market, 2015-2025, $Billion
  • Table 119: Africa Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Table 120: Africa Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Table 121: Africa Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Table 122: Africa Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
  • Table 123: Global Cancer Monoclonal Antibodies Market, Key Competitor Estimated Market Shares, 2020, Percentage (%)
  • Table 124: F. Hoffmann-La Roche Ltd – Financial Performance, 2016 – 2020, $ Billion
  • Table 125: Merck & Co., Inc. – Financial Performance, 2016 – 2020, $ Billion
  • Table 126: Bristol Myers Squibb Company – Financial Performance, 2016 – 2020, $ Billion
  • Table 127: Johnson & Johnson – Financial Performance, 2016 – 2020, $ Billion
  • Table 128: Amgen Inc. – Financial Overview, 2016 - 2020, $ Billion
  • Table 129: Global Cancer Monoclonal Antibodies Market Size Gain ($ Million), 2020 – 2025, By Country
  • Table 130: Global Cancer Monoclonal Antibodies Market Size Gain ($ Million), Segmentation By Monoclonal Antibody Therapies, 2020 – 2025
  • Table 131: Global Cancer Monoclonal Antibodies Market Size Gain ($ Million), Segmentation By Application, 2020 – 2025
  • Table 132: Global Cancer Monoclonal Antibodies Market Size Gain ($ Million), Segmentation By End User, 2020 – 2025
  • Table 133: Cancer Monoclonal Antibodies - Market Data Sources

List Of Figures

    Figure 1: Global Cancer Monoclonal Antibodies Market Segmentation By Monoclonal Antibody Therapies
  • Figure 2: Global Cancer Monoclonal Antibodies Market Segmentation By Application
  • Figure 3: Global Cancer Monoclonal Antibodies Market Segmentation By End User
  • Figure 4: Global Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Figure 5: Global Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 6: Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 7: Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 8: Global Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 9: Global Cancer Monoclonal Antibodies Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 10: Global Cancer Monoclonal Antibodies Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 11: Asia-Pacific Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Figure 12: Asia-Pacific Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 13: Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 14: China Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Figure 15: China Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 16: China Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 17: India Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Figure 18: India Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 19: India Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 20: Japan Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Figure 21: Japan Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 22: Japan Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 23: Australia Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Figure 24: Australia Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 25: Australia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 26: Indonesia Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Figure 27: Indonesia Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 28: Indonesia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 29: South Korea Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Figure 30: South Korea Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 31: South Korea Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 32: Western Europe Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Figure 33: Western Europe Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 34: Western Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 35: UK Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Figure 36: UK Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 37: UK Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 38: Germany Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Figure 39: Germany Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 40: Germany Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 41: France Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Figure 42: France Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 43: France Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 44: Eastern Europe Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Figure 45: Eastern Europe Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 46: Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 47: Russia Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Figure 48: Russia Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 49: Russia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 50: North America Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Figure 51: North America Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 52: North America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 53: USA Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Figure 54: USA Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 55: USA Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 56: South America Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Figure 57: South America Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 58: South America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 59: Brazil Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Figure 60: Brazil Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 61: Brazil Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 62: Middle East Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Figure 63: Middle East Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 64: Middle East Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 65: Africa Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
  • Figure 66: Africa Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
  • Figure 67: Africa Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
  • Figure 68: Global Cancer Monoclonal Antibodies Market, Key Competitor Estimated Market Shares, 2020, Percentage (%)
  • Figure 69: F. Hoffmann-La Roche Ltd – Financial Performance, 2016 – 2020, $ Billion
  • Figure 70: Merck & Co., Inc. – Financial Performance, 2016 – 2020, $ Billion
  • Figure 71: Bristol Myers Squibb Company – Financial Performance, 2016 – 2020, $ Billion
  • Figure 72: Johnson & Johnson – Financial Performance, 2016 – 2020, $ Billion
  • Figure 73: Amgen Inc. – Financial Overview, 2016 – 2020, $ Billion
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report